A longevity startup has administered its first dose of a cellular rejuvenation therapy to a patient. The move follows recent FDA approval for human clinical trials of the treatment known as ER-100.
The therapy targets age-related sight loss as its initial focus. Company officials confirmed the dosing took place after regulators cleared the drug for trials. Vision restoration is the primary goal at this stage. The treatment may later address other conditions tied to aging. This marks an early step in efforts to apply cellular rejuvenation methods in people. The startup has not released details on the patient's condition or trial location.
